Join in June to score a special gift!

Expert Q&A: Gene-Editing Treatment for Sickle Cell Disease May Be Out of Reach for Many

December 8, 2023


Read time:

<5 mins
Sickle Cells Blood Vessels 0

Newly approved by the FDA, CRISPR-based Exa-cel gene editing technology can potentially treat thousands of patients with sickle cell disease. However, this new therapy is expensive and intense and, to start will only be offered by a few healthcare providers. In this Q&A with the Institute for Healthcare Policy and Innovation, Melissa Creary, Ph.D., an assistant professor of health management policy and global public health at U-M’s School of Public Health and a person living with sickle cell, brings her perspective to the conversation about the accessibility of this breakthrough treatment.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.